Power Law company profile

Surface Oncology

Biotech & Life Sciences · Cambridge, United States · Founded 2014 · IPO 2018 Thoroughbred

Surface Oncology was created to advance next-generation approaches to cancer immunotherapy based on proprietary insights

Valuation

$18M

Market cap · 2026

Revenue

$30M

Latest reported FY

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

5 investors on Surface Oncology's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 2 investors entered at this stage

Atlas Venture

Eight Roads Ventures

Series A 3 investors entered at this stage

NEA

Lilly Ventures

F-Prime

Global footprint

Where Surface Oncology has talent and traffic

Workforce by country

🇺🇸 United States · Cambridge HQ

Book a demo for the full country breakdown

Market sentiment

What the market is saying about Surface Oncology

An AI-synthesized read of the highest-engagement posts about Surface Oncology on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Surface Oncology on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles